Circus SE Appoints Former Helsing Top-Executive Sasha Borovik as General Counsel
MUNICH--(BUSINESS WIRE)--Circus SE (XETRA: CA1), a global leader in AI software and robotics for the food service industry, announces the appointment of Sasha Borovik as General Counsel effective June 11, 2025.
A graduate of Harvard Law School with over two decades of global legal and commercial leadership, Borovik has negotiated complex technology, defense, and AI transactions on behalf of major corporations and institutions. His track record spans work with NATO-aligned governments, the UN, and AI leaders shaping next-generation defense infrastructure.
At Helsing, Europe's leading defense AI company, Borovik played a pivotal role as General Counsel and Director of Compliance - not only building the legal function, but also leading the structuring and execution of multiple capital rounds totaling over $800 million to date. His legal leadership was instrumental in navigating dual-use technology regulation, defense contracting, and IP protection in one of Europe's most strategically important AI ventures.
Prior to Helsing, Borovik served as Senior Director and Lead Counsel for EMEA at Akamai Technologies (Nasdaq: AKAM), and Director of Legal Affairs at Microsoft (Nasdaq: MSFT) as a head lawyer for the public sector, where he supported global expansion, strategic partnerships, and high-value commercial transactions across regulated markets.
Borovik's appointment comes as Circus prepares for the launch of its CA-M defense product line, the world's first autonomous meal supply system designed for defense and critical infrastructure, and ramps up serial production of its core CA-1 system. As the company's first core defense executive, he will play a critical role in shaping commercial agreements, institutional partnerships, and regulatory strategy across dual-use domains.
'Joining Circus is an opportunity to shape the strategic and legal backbone of a company that's redefining autonomy at scale,' said Sasha Borovik. 'With the CA-M and a growing international footprint, Circus is stepping into domains where legal rigor and regulatory foresight are not just an asset - they're mission-critical.'
'Sasha brings a rare combination of legal excellence, deal-making experience, and deep domain knowledge in defense and AI,' said Nikolas Bullwinkel, CEO and Founder of Circus SE. 'As we expand negotiations with multiple NATO-aligned forces and scale internationally, his leadership will be instrumental in building robust, long-term partnerships.'
Borovik holds law degrees from Harvard Law School and Charles University in Prague. He speaks seven languages and is admitted to the bar in both the European Union and the state of New York.
About Circus SE
Circus SE (XETRA: CA1) is a global AI and robotics company developing autonomous systems for food supply in both civilian and defense sectors. Its flagship robot, the patented CA-1, is the world's first fully autonomous food production robot, now in serial production. Powered by proprietary embodied AI, Circus delivers industrial-scale, high-reliability meal output with minimal human input. Headquartered in Munich, the company is building the global infrastructure for autonomous food supply — on a mission to fuel humanity.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
National CineMedia (NASDAQ:NCMI) investors are sitting on a loss of 79% if they invested five years ago
Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. Anyone who held National CineMedia, Inc. (NASDAQ:NCMI) for five years would be nursing their metaphorical wounds since the share price dropped 83% in that time. Furthermore, it's down 11% in about a quarter. That's not much fun for holders. While a drop like that is definitely a body blow, money isn't as important as health and happiness. Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Because National CineMedia made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. Over five years, National CineMedia grew its revenue at 1.6% per year. That's not a very high growth rate considering it doesn't make profits. Nonetheless, it's fair to say the rapidly declining share price (down 13%, compound, over five years) suggests the market is very disappointed with this level of growth. We'd be pretty cautious about this one, although the sell-off may be too severe. We'd recommend focussing any further research on the likelihood of profitability in the foreseeable future, given the muted revenue growth. You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image). You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic. It is important to consider the total shareholder return, as well as the share price return, for any given stock. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, National CineMedia's TSR for the last 5 years was -79%, which exceeds the share price return mentioned earlier. And there's no prize for guessing that the dividend payments largely explain the divergence! We're pleased to report that National CineMedia shareholders have received a total shareholder return of 19% over one year. That's including the dividend. There's no doubt those recent returns are much better than the TSR loss of 12% per year over five years. This makes us a little wary, but the business might have turned around its fortunes. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with National CineMedia , and understanding them should be part of your investment process. But note: National CineMedia may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
York Water (NASDAQ:YORW) shareholders have endured a 26% loss from investing in the stock five years ago
The main aim of stock picking is to find the market-beating stocks. But every investor is virtually certain to have both over-performing and under-performing stocks. So we wouldn't blame long term The York Water Company (NASDAQ:YORW) shareholders for doubting their decision to hold, with the stock down 33% over a half decade. Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. During the unfortunate half decade during which the share price slipped, York Water actually saw its earnings per share (EPS) improve by 2.6% per year. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Alternatively, growth expectations may have been unreasonable in the past. By glancing at these numbers, we'd posit that the the market had expectations of much higher growth, five years ago. Having said that, we might get a better idea of what's going on with the stock by looking at other metrics. Revenue is actually up 8.6% over the time period. A more detailed examination of the revenue and earnings may or may not explain why the share price languishes; there could be an opportunity. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). It's probably worth noting that the CEO is paid less than the median at similar sized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. So it makes a lot of sense to check out what analysts think York Water will earn in the future (free profit forecasts). When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. In the case of York Water, it has a TSR of -26% for the last 5 years. That exceeds its share price return that we previously mentioned. This is largely a result of its dividend payments! Investors in York Water had a tough year, with a total loss of 9.3% (including dividends), against a market gain of about 12%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 5% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - York Water has 2 warning signs (and 1 which is significant) we think you should know about. If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Bloomberg
an hour ago
- Bloomberg
NATO Offers to Tweak 5% Spending Goal to Win Spanish Approval
NATO has offered to tweak key language on ambitious defense spending targets to help win support from holdout Spain, before leaders of the military alliance gather on Tuesday. The draft statement to be adopted at the June 24-25 summit will be changed to 'allies' commit to spending 5% of GDP on defense from 'we' commit, according to people familiar with the talks.
